

=====

Sequence Listing was accepted.

If you need help call the Patent Electronic Business Center at (866)  
217-9197 (toll free).

Reviewer: Keisha Douglas

Timestamp: [year=2008; month=8; day=25; hr=16; min=57; sec=56; ms=443; ]

=====

Application No: 10533103

Version No: 2.0

Input Set:

Output Set:

Started: 2008-07-23 11:22:48.409

Finished: 2008-07-23 11:22:49.026

Elapsed: 0 hr(s) 0 min(s) 0 sec(s) 617 ms

Total Warnings: 6

Total Errors: 0

No. of SeqIDs Defined: 14

Actual SeqID Count: 14

Error code	Error Description
W 213	Artificial or Unknown found in <213> in SEQ ID (9)
W 213	Artificial or Unknown found in <213> in SEQ ID (10)
W 213	Artificial or Unknown found in <213> in SEQ ID (11)
W 213	Artificial or Unknown found in <213> in SEQ ID (12)
W 213	Artificial or Unknown found in <213> in SEQ ID (13)
W 213	Artificial or Unknown found in <213> in SEQ ID (14)

# SEQUENCE LISTING

<110> National Institutes of Health  
 Bocharov, Alexander  
 Baranova, Irina  
 Csako, Gyorgy  
 Eggerton, Thomas  
 Patterson, Amy  
 Remaley, Alan  
 Vishnyakova, Tatyana

<120> Scavenger Receptor B1 Targeting for the Treatment of Infection,  
 Sepsis and Inflammation

<130> 03514.115-PCT

<140> 10533103  
 <141> 2008-07-23

<150> 60/422,105  
 <151> 2002-10-30

<160> 14

<170> PatentIn version 3.2

<210> 1  
 <211> 21  
 <212> DNA  
 <213> Homo sapiens

<400> 1  
 gtcttcacca ccatggagaa g 21

<210> 2  
 <211> 25  
 <212> DNA  
 <213> Homo sapiens

<400> 2  
 gcttcaccac cttcttgatg tcac 25

<210> 3  
 <211> 21  
 <212> DNA  
 <213> Homo sapiens

<400> 3  
 ccaccaacg aaggcttctg c 21

<210> 4  
 <211> 19  
 <212> DNA  
 <213> Homo sapiens

<400> 4  
ctgaatggcc tccttatcc 19

<210> 5  
<211> 20  
<212> DNA  
<213> Homo sapiens

<400> 5  
caactacaaa gccctctttg 20

<210> 6  
<211> 20  
<212> DNA  
<213> Homo sapiens

<400> 6  
cttggctggt ctccatgaag 20

<210> 7  
<211> 18  
<212> DNA  
<213> Homo sapiens

<400> 7  
ctgaaagctc tccacctc 18

<210> 8  
<211> 18  
<212> DNA  
<213> Homo sapiens

<400> 8  
gtgctgatgt accagttg 18

<210> 9  
<211> 18  
<212> PRT  
<213> Artificial Sequence  
<220>  
<223> Synthetic construct

<400> 9  
  
Asp Trp Leu Lys Ala Phe Tyr Asp Lys Val Ala Glu Lys Leu Lys Glu  
1 5 10 15

Ala Phe

<210> 10  
<211> 37  
<212> PRT  
<213> Artificial Sequence  
<220>  
<223> Synthetic construct

<400> 10

Asp Trp Leu Lys Ala Phe Tyr Asp Lys Val Ala Glu Lys Leu Lys Glu  
1 5 10 15

Ala Phe Pro Asp Trp Leu Lys Ala Phe Tyr Asp Lys Val Ala Glu Lys  
20 25 30

Leu Lys Glu Ala Phe  
35

<210> 11  
<211> 37  
<212> PRT  
<213> Artificial Sequence  
<220>  
<223> Synthetic construct

<220>  
<221> MISC\_FEATURE  
<222> (1)..(37)  
<223> All residues D-Amino Acid

<400> 11

Asp Trp Leu Lys Ala Phe Tyr Asp Lys Val Ala Glu Lys Leu Lys Glu  
1 5 10 15

Ala Phe Pro Asp Trp Leu Lys Ala Phe Tyr Asp Lys Val Ala Glu Lys  
20 25 30

Leu Lys Glu Ala Phe  
35

<210> 12  
<211> 37  
<212> PRT  
<213> Artificial Sequence  
<220>  
<223> Synthetic construct

<220>  
<221> MISC\_FEATURE

<222> (1)..(37)

<223> All Ala residues are D-Amino Acids

<400> 12

Asp Trp Leu Lys Ala Phe Tyr Asp Lys Val Ala Glu Lys Leu Lys Glu  
1 5 10 15

Ala Phe Pro Asp Trp Leu Lys Ala Phe Tyr Asp Lys Val Ala Glu Lys  
20 25 30

Leu Lys Glu Ala Phe  
35

<210> 13

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic construct

<220>

<221> MISC\_FEATURE

<222> (1)..(37)

<223> All Tyr and Val are D-Amino Acid Residues

<400> 13

Asp Trp Leu Lys Ala Phe Tyr Asp Lys Val Ala Glu Lys Leu Lys Glu  
1 5 10 15

Ala Phe Pro Asp Trp Leu Lys Ala Phe Tyr Asp Lys Val Ala Glu Lys  
20 25 30

Leu Lys Glu Ala Phe  
35

<210> 14

<211> 37

<212> PRT

<213> Artificial Sequence

<220>

<223> Synthetic construct

<220>

<221> MISC\_FEATURE

<222> (1)..(37)

<223> All Asp, Lys and Ala are D-Amino Acid Residues

<400> 14

Asp Trp Leu Lys Ala Phe Tyr Asp Lys Val Ala Glu Lys Leu Lys Glu  
1 5 10 15

Ala Phe Pro Asp Trp Leu Lys Ala Phe Tyr Asp Lys Val Ala Glu Lys  
20 25 30

Leu Lys Glu Ala Phe  
35